HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus target price of $6.00 for the company and are anticipating that the company will post ($0.87) earnings per share for the current quarter, according to Zacks. Zacks has also given HTG Molecular Diagnostics an industry rank of 103 out of 265 based on the ratings given to related companies.

Several analysts recently commented on HTGM shares. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Rodman & Renshaw started coverage on shares of HTG Molecular Diagnostics in a research report on Monday, August 22nd. They issued a “buy” rating and a $5.00 price target for the company.

Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded up 2.47% during mid-day trading on Monday, hitting $2.49. 1,767 shares of the stock traded hands. The firm’s market cap is $17.55 million. HTG Molecular Diagnostics has a 12-month low of $2.03 and a 12-month high of $13.10. The firm’s 50 day moving average price is $2.45 and its 200 day moving average price is $2.70.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.95) by $0.03. On average, equities research analysts predict that HTG Molecular Diagnostics will post ($3.58) EPS for the current fiscal year.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

5 Day Chart for NASDAQ:HTGM

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.